FEMASYS INC

FEMY
About the company

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.

Country: United StatesPrice: $1.42Market Cap: $11.9M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #3018 (Top 97.4%)FAILFAILFAILFAILFAILFAILPASSPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio14.5x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-303.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-303.0%, ROC=-322.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share14.5x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-22.1%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-161.6%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=14.5x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low104% of trailing low ($1.37)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-98.95%; #5387/6340 (top 85.0%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.3389; #3513/6449 (top 54.5%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share14.84x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.1934; #3816/5247 (top 72.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-151.98%; #4157/4519 (top 92.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-82.12%; #5861/6202 (top 94.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✗ 12▾

      All 10 investors flag FEMY's cash flow

      Free Cash Flow Proxy$-18.6M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-18.1M
      ✗LynchPositive and growing
      Operating Cash Flow$-18.7M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-90.19%, ROA=-89.88%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-161.6%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/6 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-21.2%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/6 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-18.1M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-151.98%; #4157/4519 (top 92.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability6% pass✓ 3✗ 32▾

      15 of 16 flag FEMY's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/7 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/7 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-263.0%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-767.0% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-18.6M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-291.9%
      ✗Lynch> 15%
      EBIT / Enterprise Value-303.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-303.0%, ROC=-322.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-89.88%
      ✗PiotroskiROA > 0
      ROA Change YoY-151.20% -> -89.88% (delta: +61.31%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-90.19%, ROA=-89.88%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY66.6% -> 62.0%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-511.5%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-291.9%
      ✗Dreman> 12%
      Margin of SafetyP/B=14.5x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-403.9% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-763.9%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-291.9%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-1353.4% (2023) -> -767.0% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 64.5% -> 62.0%, operating margin -1353.4% -> -767.0%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-98.95%; #5387/6340 (top 85.0%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+6.86%; #3003/3702 (top 81.1%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-291.94%; #4976/5226 (top 95.2%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.4239; #4844/5884 (top 82.3%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/6 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts13% pass✓ 2✗ 14▾

      Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #3018✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2368/2370 (Top 99.9%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Growth25% pass✓ 5✗ 8▾

      6 of 8 flag FEMY's growth — Graham, Lynch, Dreman +3 more

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 18.3% vs Rev: 21.9%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-7.20 (2020) -> $-0.47 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth40.8%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency5/5 years with positive EPS growth
      ✓AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 64.5% -> 62.0%, operating margin -1353.4% -> -767.0%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR17.2%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag FEMY's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio2.14
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-363.0%
      ✗Buffett> 10%
      ROIC - WACC-373.0%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-322.8%
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.93 -> 4.53
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.13x -> 0.11x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities2.14
      ✓Dreman> 1.5
      Return on Invested Capital-183.7%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-62.5%; FY2024: ROIC=-182.2%; FY2025: ROIC=-153.6%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -153.6%)
      ✗SleepROIC > 12% in a majority of years
    • Debt & Leverage33% pass✓ 6✗ 9▾

      8 of 12 flag FEMY's debt & leverage — Graham, Buffett, Lynch +5 more

      Total Debt / Shareholders' Equity0.87
      ✗Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.87, IC: -13.5x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.87
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.14
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Debt Levels0.87
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-13.5x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.87
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.8735; #3068/4210 (top 72.9%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($11.9M)
    Revenue: $2.3M+40.8% YoY
    Net Income: $18.6M+1.0% YoY

    Financial Snapshot

    Operating Margin-767.0%
    Return on Equity-317.4%
    Debt / Equity0.54
    Current Ratio4.53
    EPS (Diluted)$-0.47

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-03-27
    FY 2023
    Sources
    • 10-K · 2024-03-28
    FY 2022
    Sources
    • 10-K · 2023-03-30
    FY 2021
    Sources
    • 10-K · 2022-03-24
    Market Cap$11.9Mcurrent------$32.1Mest.$27.4Mest.$16.1Mest.$14.3Mest.$35.1Mest.
    Revenue$2.0M↓4%$404.6K↓45%$331.8K↓19%$424.9K↑25%$2.3M↑41%$1.6M↑52%$1.1M↓11%$1.2M↑2%$1.2M
    Operating Income-$18.4M↓4%-$4.5M↓22%-$5.1M↓32%-$4.2M↑23%-$17.6M↑1%-$17.8M↓23%-$14.5M↓25%-$11.6M↓39%-$8.3M
    Net Income-$12.1M↑39%-$4.6M↓9%-$4.5M↑3%$846.1K↑114%-$18.6M↑1%-$18.8M↓32%-$14.2M↓25%-$11.4M↓51%-$7.5M
    EPS (Diluted)--$-0.53↓430%$-1.33↓731%$0.00↑100%$-0.47↑45%$-0.85↑9%$-0.93↑3%$-0.96↑14%$-1.12
    Gross Margin————62.0%↓7%66.6%↑3%64.5%↑2%63.4%↓8%68.6%
    Operating Margin-929.9%↓8%-1099.9%↓120%-1526.7%↓62%-994.0%↑38%-767.0%↑30%-1091.8%↑19%-1353.4%↓41%-961.7%↓36%-706.7%
    ROE-44.9%↑90%———-317.4%↑61%-816.5%↓952%-77.6%↓4%-74.8%↓161%-28.6%
    Total Debt$3.7M↑1245%$3.7M↑1245%$3.5M↓42%$3.3M↓42%$3.2M↓41%$5.4M$0↓100%$141.3K↓22%$181.1K
    Shareholders' Equity$27.0M↑493%$27.0M↑493%$4.0M↑167%$7.3M↑265%$5.9M↑155%$2.3M↓87%$18.4M↑20%$15.2M↓42%$26.3M
    Current Ratio8.67↑646%8.67↑646%2.14↑141%3.91↑322%4.53↑384%0.93↓88%7.59↓18%9.25↓39%15.15
    Debt / Equity0.14↑127%0.14↑127%0.87↓78%0.46↓84%0.54↓77%2.350.00↓100%0.01↑35%0.01
    Operating Cash Flow-$17.1M↑13%-$4.8M↑11%-$3.9M↑10%-$4.1M↑13%-$18.7M↑4%-$19.4M↓72%-$11.3M↓5%-$10.7M↓35%-$7.9M
    Free Cash Flow-$17.3M↑14%-$4.8M↑13%-$3.9M↑11%-$4.2M↑13%-$19.2M↑5%-$20.2M↓77%-$11.4M↓3%-$11.1M↓35%-$8.2M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    FEMY vs Peers — Financial Grading

    Revenue$2.3MBottom 25%
    Net Income$18.6MBottom 25%
    ROE-317.4%Bottom 25%
    D/E0.54Median
    Op. Margin-767.0%Bottom 25%
    Curr. Ratio4.53Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11